Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses

G. B. Calandra; L. J. Lukacs; L. C. Jonas; M. Santosham; J. I. Ward; D. P. Greenberg; R. S. Daum; H. Matthews; P. P. Vella; J. L. Ryan

doi:10.1016/0264-410X(93)90162-Q

Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses

G. B. Calandra, L. J. Lukacs, L. C. Jonas, M. Santosham, J. I. Ward, D. P. Greenberg, R. S. Daum, H. Matthews, P. P. Vella, J. L. Ryan

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

The Haemophilus influenzae capsular polysaccharide-outer membrane protein conjugate, PRP-OMPC (PedvaxHIB) elicits very good antibody responses in infants ≥ 2 months of age after the first dose. Increasing age at time of first vaccination correlates with higher antibody responses. Anti-PRP responses are consistently high with the first injection among all population groups studied. Booster doses stimulate anamnestic antibody responses after one year of age. Among US children (excluding Navajo and Apache children) given a primary injection at 14-18 months of age, the geometric mean titre (GMT) after 2 to 3 years was >1 μg/ml. US children (excluding Navajo and Apache children) given a primary series at 2 and 4 months of age and a booster at 18 months of age also had an anti-PRP GMT >1 μg/ml 2.5 years later. Navajo and Apache children given a primary series at 2 and 4 months of age and a booster at 12-15 months had antibody levels of 1.50 μg/ml one year later. Antibody persistence data suggest there will be long-term protection against Haemophilus influenzae b disease following immunization with PRP-OMPC.

Original language	English
Pages (from-to)	S58-S62
Journal	Vaccine
Volume	11
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/0264-410X(93)90162-Q
State	Published - 1 Jan 1993
Externally published	Yes

Keywords

Haemophilus influenzae
PRP conjugate vaccine
antibody persistence

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0264-410X(93)90162-Q

Cite this

@article{595aea825c8f4ac688df3cddf7f315e1,

title = "Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses",

abstract = "The Haemophilus influenzae capsular polysaccharide-outer membrane protein conjugate, PRP-OMPC (PedvaxHIB) elicits very good antibody responses in infants ≥ 2 months of age after the first dose. Increasing age at time of first vaccination correlates with higher antibody responses. Anti-PRP responses are consistently high with the first injection among all population groups studied. Booster doses stimulate anamnestic antibody responses after one year of age. Among US children (excluding Navajo and Apache children) given a primary injection at 14-18 months of age, the geometric mean titre (GMT) after 2 to 3 years was >1 μg/ml. US children (excluding Navajo and Apache children) given a primary series at 2 and 4 months of age and a booster at 18 months of age also had an anti-PRP GMT >1 μg/ml 2.5 years later. Navajo and Apache children given a primary series at 2 and 4 months of age and a booster at 12-15 months had antibody levels of 1.50 μg/ml one year later. Antibody persistence data suggest there will be long-term protection against Haemophilus influenzae b disease following immunization with PRP-OMPC.",

keywords = "Haemophilus influenzae, PRP conjugate vaccine, antibody persistence",

author = "Calandra, {G. B.} and Lukacs, {L. J.} and Jonas, {L. C.} and M. Santosham and Ward, {J. I.} and Greenberg, {D. P.} and Daum, {R. S.} and H. Matthews and Vella, {P. P.} and Ryan, {J. L.}",

year = "1993",

month = jan,

day = "1",

doi = "10.1016/0264-410X(93)90162-Q",

language = "English",

volume = "11",

pages = "S58--S62",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses

AU - Calandra, G. B.

AU - Lukacs, L. J.

AU - Jonas, L. C.

AU - Santosham, M.

AU - Ward, J. I.

AU - Greenberg, D. P.

AU - Daum, R. S.

AU - Matthews, H.

AU - Vella, P. P.

AU - Ryan, J. L.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The Haemophilus influenzae capsular polysaccharide-outer membrane protein conjugate, PRP-OMPC (PedvaxHIB) elicits very good antibody responses in infants ≥ 2 months of age after the first dose. Increasing age at time of first vaccination correlates with higher antibody responses. Anti-PRP responses are consistently high with the first injection among all population groups studied. Booster doses stimulate anamnestic antibody responses after one year of age. Among US children (excluding Navajo and Apache children) given a primary injection at 14-18 months of age, the geometric mean titre (GMT) after 2 to 3 years was >1 μg/ml. US children (excluding Navajo and Apache children) given a primary series at 2 and 4 months of age and a booster at 18 months of age also had an anti-PRP GMT >1 μg/ml 2.5 years later. Navajo and Apache children given a primary series at 2 and 4 months of age and a booster at 12-15 months had antibody levels of 1.50 μg/ml one year later. Antibody persistence data suggest there will be long-term protection against Haemophilus influenzae b disease following immunization with PRP-OMPC.

AB - The Haemophilus influenzae capsular polysaccharide-outer membrane protein conjugate, PRP-OMPC (PedvaxHIB) elicits very good antibody responses in infants ≥ 2 months of age after the first dose. Increasing age at time of first vaccination correlates with higher antibody responses. Anti-PRP responses are consistently high with the first injection among all population groups studied. Booster doses stimulate anamnestic antibody responses after one year of age. Among US children (excluding Navajo and Apache children) given a primary injection at 14-18 months of age, the geometric mean titre (GMT) after 2 to 3 years was >1 μg/ml. US children (excluding Navajo and Apache children) given a primary series at 2 and 4 months of age and a booster at 18 months of age also had an anti-PRP GMT >1 μg/ml 2.5 years later. Navajo and Apache children given a primary series at 2 and 4 months of age and a booster at 12-15 months had antibody levels of 1.50 μg/ml one year later. Antibody persistence data suggest there will be long-term protection against Haemophilus influenzae b disease following immunization with PRP-OMPC.

KW - Haemophilus influenzae

KW - PRP conjugate vaccine

KW - antibody persistence

UR - http://www.scopus.com/inward/record.url?scp=18144452753&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(93)90162-Q

DO - 10.1016/0264-410X(93)90162-Q

M3 - Article

AN - SCOPUS:18144452753

SN - 0264-410X

VL - 11

SP - S58-S62

JO - Vaccine

JF - Vaccine

IS - SUPPL. 1

ER -

Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this